Back to Journals » OncoTargets and Therapy » Volume 10

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

Authors Levin PA, Dowell JE

Received 23 December 2016

Accepted for publication 11 March 2017

Published 7 April 2017 Volume 2017:10 Pages 2057—2066

DOI https://doi.org/10.2147/OTT.S113598

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 3

Editor who approved publication: Dr Yao Dai

Pavel A Levin,1 Jonathan E Dowell1,2

1Division of Hematology/Oncology, University of Texas Southwestern Medical Center, 2Section of Hematology/Oncology, Veteran Affairs North Texas Health Care System, Dallas, TX, USA


Abstract: Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as important players in the biology of this disease. Bevacizumab is a monoclonal antibody that binds VEGF and blocks its interaction with the VEGF receptor. Recent studies have shown benefit with the addition of bevacizumab to the combination of cisplatin and pemetrexed in MPM. This combination is now included in the National Comprehensive Cancer Network guidelines (with a category 2A recommendation) as a possible first-line treatment for unresectable MPM in appropriately selected patients. This review discusses the rationale behind the use of bevacizumab in MPM, as well as summarizes the pharmacology, efficacy, safety, and toxicity of bevacizumab across multiple trials. The use of small-molecule inhibitors of angiogenesis in the treatment of MPM is also discussed.

Keywords: angiogenesis, monoclonal antibody, VEGF

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Modern management of malignant pleural mesothelioma

Patel SC, Dowell JE

Lung Cancer: Targets and Therapy 2016, 7:63-72

Published Date: 3 May 2016